A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGL
Status:
Recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies the effectiveness oftemozolomide in the neoadjuvant therapy
oflocally advanced,or unresectable pheochromocytoma or paragangliom(PPGL). Temozolomide (TMZ)
is a novel oral alkylation chemotherapeutic agent. Inthisstudy,temozolomidewill be used
preoperatively in order to change unresectable tumors to resectable and reduce the high risk
of surgery.